wrn offer solid synthet lethal base
revenu pkc inhibitor initi
outperform pt
initi coverag idya outperform rate price target base
posit outlook potenti pkc inhibitor improv
current soc metastat uveal melanoma mum grow support literatur
synthet lethal strategi target wrn pol-theta potenti
idya first-to-market compound treat one target
forecast peak sale base durat therapi
current best soc believ idya current valuat reflect
limit investor awar follow may ipo littl valu pipelin beyond
limit peer group publicli trade synthet lethal compani
sale forecast base two assumpt mum
patient record least month soc activ solid tumor
gnaq mutat drug achiev profil view
potenti record peak revenu gross sale
revenu us
near-term clariti mum regulatori path idya meet fda
discuss registr studi mum base case assum fda single-
arm registr studi due limit clinic benefit offer altern therapi
believ primari endpoint single-arm studi like orr
basket studi offer upsid stori data describ anti-tumor
activ gnaq mutant solid tumor outsid mum limit idya
launch basket studi identifi tumor type may benefit
studi posit address market gnaq mutant solid tumor
least larger mum
wrn promis synthet lethal target recent paper
sanger institut broad institut creat roadmap priorit
potenti target synthet lethal studi identifi wrn helicas
promis target par kra term potenti clinic benefit
also score well sanger studi idya develop compound
healthi near-term news focus phase data first-
in-class inhibitor octob
aacr-nci-eortc meet may offer clinic valid target
data basket studi posit solid tumor
could expand address market
year price histori idya
pkc
treatment
metastat uveal melanoma
portfolio synthet
analyst certif import disclosur see disclosur
pck inhibit regul mapk signal
upstream gnaq mutat offer attract
strategi treat metastat uveal melanoma base broad
express gnaq mutat popul
patient early-stag proof-of-concept clinic
trial forecast call gener peak sale
base month popul
treatment altern intermedi term expect one
idya synthet lethal drug candid move
clinic develop potenti offer first-in-class best-
in-class potenc profil progress synthet lethal
compound would offer upsid outlook
parp inhibitor valid synthet lethal attract modal
develop target therapi treat solid tumor
among idya four disclos synthet lethal program one
eventu lead commerci product
fda approv mum base singl arm studi
orr primari endpoint
activ solid tumor loss function mutat
gnaq support commerci use beyond mum
success meet fda defin studi design mum
registr studi singl arm compar
updat efficaci data phase i/ii mum studi
interim data basket studi gnaq
loss function solid tumor ex mum
phase data anoth synthet lethal drug
combin regimen mek inhibitor target agent
extend durat treatment mum
use sequenc newli diagnos cancer patient acceler
us commun practic outsid us lead patient
screen gnaq
competitor valid clinic relev target offer
idya opportun develop potenti potent fast follow
compani optim potent molecul wrn offer
potenti first-to-market posit one attract
fail demonstr activ basket studi solid tumor
patient gnaq loss function mutat
fda requir control arm registr studi mum
result longer-than-expect develop timelin
demonstr clinic relev benefit
registr studi mum
synthet lethal target demonstr
clinic relev target druggabl exist small
price target base dcf analysi assum discount rate million share fulli dilut basi termin year
long-term growth rate
risk idya includ clinic trial failur phase i/ii metastat uveal melanoma studi basket studi gnaq
mutant solid tumor current cash balanc suffici fund oper beyond middl pkc repres
novel target oncolog drug develop limit clinic valid prior clinic trial uncertain clinic relev
much compani portfolio may commerci partnership
initi outperform pt
initi coverag ideaya bioscienc inc outperform rate price
target base posit outlook potenti protein kinas pkc inhibitor
improv current soc metastat uveal melanoma mum grow support literatur
rang addit oncolog target amen synthet lethal strategi includ
wrn pol-theta parg potenti idya first-to-market compound treat one
target recent data esmo suggest broader benefit parp inhibitor
breast cancer ovarian cancer view first-gener synthet lethal compound
gain clinic accept set stage rapid develop second-gener
compound believ idya current valuat reflect limit investor
awar follow may ipo little-to-no valu pipelin beyond limit
peer group publicli trade synthet lethal compani
rel immune-oncolog cell therapi numer segment oncolog drug
develop view target therapi enjoy less intens competit favor
opportun develop multipl first-in-class compound parallel furthermor view
competit environ conduc activ
overal believ street correctli model commerci opportun
forecast peak sale assum market penetr mum us single-digit
penetr solid tumor share among mum patient europ
durat therapi current best soc monthli price
us model call launch us seek partner
pt base dcf analysi assum discount rate million share fulli
dilut basi termin year base sole sale termin
revenu growth rate methodolog point includ contribut pipelin beyond
forecast reflect potenti econom contribut pipelin higher
revenu growth rate dcf forecast vs standard biotech compani
regard news flow focus meet fda discuss mum registr studi
design phase data first-in-class inhibitor
octob aacr-nci-eortc meet may offer clinic valid target
data basket studi posit solid tumor
parp inhibitor first clinic import class synthet lethal compound
develop multipl compound ovarian breast prostat cancer present four
studi presidenti session esmo recent fda approv olaparib frontlin
mainten therapi brca ovarian cancer base result studi view first-
gener synthet lethal compound gain broad clinic accept importantli recent
studi better inform use drug combin class therapi
includ chemotherapi anti-angiogen agent experi improv pace
clinic develop second-gener synthet lethal program view
intermedi term expect clinic accept synthet lethal translat increas busi
develop interest larg pharma
diversif necessari mitig target risk
net view preclin model less predict clinic efficaci synthet lethal
compound tradit target therapi strategi tki gene fusion addit
develop parp inhibitor highlight variat target bind result signific
differ advers event profil abil combin chemotherapi short view clinic
valid necessari predict potenc higher-than-averag risk failur earli clinic
develop target drug develop strategi believ broad
pipelin may necessari build sustain busi model synthet lethal compound
valid product metastat uveal melanoma sale
prior studi patient receiv bid dose demonstr diseas control rate
includ orr better single-digit respons rate previous report dtic
chemotherapi dataset small major pr durabl patient remain
therapi month peak sale estim base two assumpt mum patient
record least month soc result market penetr us
solid tumor gnaq loss function mutat enjoy compar benefit
drug achiev profil view potenti record peak revenu
gross sale revenu us
two assumpt view activ gnaq mutant solid tumor
beyond mum enjoy limit support literatur also offer greatest econom upsid
base address market least larger mum
view wrn promis pipelin program
advent crispr technolog sever academ group sought replic
condit synthet lethal intervent single-strand target dna break evalu
biolog activ potenti therapeut target differ cancer cell line recent paper sanger
institut broad institut creat roadmap priorit potenti target synthet lethal
like acceler invest sector sanger institut publish method
use crispr screen priorit cancer therapeut target describ april issu
natur lab screen human cancer cell line cancer type wrn
score well studi
believ current directli compar publicli trade synthet lethal
compani creat challeng benchmark valuat select bia result
higher-qu first-gener parp inhibitor acquir glaxosmithklin paid tesaro
weaker asset left languish public market clovi oncolog rucaparib
furthermor view tki gene fusion turn appropri
compar base differ level target valid believ sever high-
qualiti privat held synthet lethal compani view one may seek enter
public market next month would view matur peer group well-
manag competitor gener support higher valuat group includ idya
specif focus ksq therapeut artio
pharma
price target share idya base discount cash flow dcf model sale
mum colon cancer endometri carcinoma skin cutan melanoma
includ contribut pipelin program
model call compani maintain us commerci right receiv tier
royalti sale region expect compani achiev profit
begin pay tax effect rate
forecast call peak sale termin year revenu
us sale final year dcf valuat forecast free cash flow driven
global sale appli discount rate long-term revenu growth rate fulli
dilut share count million
oppenheim co inc estim compani document
view discount rate line typic discount rate compani lead
program enter phase ii clinic trial appropri given limit valid pkc inhibit
potent strategi treat metastat solid tumor potenti competit altern
therapeut modal may treat similar patient popul limit balanc sheet flexibl
base current cash balanc fund busi month
includ revenu idya pipelin beyond rather assign potenti
program long-term revenu growth rate long-term revenu growth rate
basi point standard long-term biotech growth rate
model call cash balanc fund oper middl increment capit
requir achiev profit
therapi remain area interest pharma busi develop
analyz valu publicli trade smid cap biotech compani target oncolog drug
would note high level activ past year
take commerci challeng smaller compani increas genet screen rate
identif elig patient target therapi continu drive larg pharma
exhibit summar larger notabl transact
discount revenu dilut share million incom work free cash growth cash ideaya bioscienc
exhibit summari therapi transact
view clariti path regulatori approv mum import de-risk event
idya specif idya expect meet fda discuss regulatori strategi base
case assum fda agre single-arm registr studi due limit clinic benefit offer
altern therapi believ primari endpoint single-arm studi like orr
support rel quick registr studi fda requir control arm dtic
chemotherapi regimen believ clinic outcom endpoint surviv may
oppenheim co inc estim compani document
believ investor current assign peak sale potenti base rel
small popul mum patient drug activ solid tumor
variant view address market could larger mum popul
focus top-line data basket studi variou solid tumor patient interim data may
avail import catalyst
lastli expect updat idya early-stag pipelin program
monitor progress compet inhibitor
potenti valid target phase data expect aacr-nci-eortc meet
corpor histori busi model
success develop commerci parp inhibitor treatment ovarian
cancer breast cancer prostat cancer first-gener synthet lethal compound gain
broad clinic accept idya form june presid ceo yujiro hata
fund ventur canaan partner investor valid new dna damage-repair
target treatment synthet lethal therapi helicas polymeras small
buyeracquireemonth/yearvalu acquisit billion astrazenecakudo pharmaosi lillyloxo importancedos select phase i/ii studi solid tumor discuss regulatori path potenti approv in-human inhibitor data competitor phase i/ii studi develop candid data egfr-mut nslcl ind-en studi pre-clin studi osimertinab data phase i/ii studi solid tumor ind-en studi inhibitor ind-en studi wrn inhibitor idya outperform
south san francisco-bas compani combin knowledg cancer biolog small molecul
drug discoveri translat biolog in-hous develop potenti first-in-class molecul
howev lead compound re-nam licens novarti septemb
follow complet seri round compani complet ipo may
rais per share
take drug discoveri process reli singl specif drug develop technolog
see limit read success failur one program molecul
implement compani develop strategi idya work academ lab target
valid import relationship includ trey idek lab ucsd function genom
carri combinatori crispr screen sourav bandyopadhyay lab ucsf identifi
idya in-hous expertis optim small molecul novel synthet lethal target
expect compani run global clinic develop pipelin program
believ compani build commerci organ sell target therapi us
view patient screen identif outsid us less matur like requir
larg biotech partner acquir
idya broad pipelin compound multipl potenti indic drug
complet phase mum compani discoveri effort synthet lethal target
inhibitor advanc slate begin ind enabl studi
program lead optim exhibit
idya lead drug clinical-stag program pkc inhibitor formerli known
drug demonstr proof-of-concept small market mum patient roughli
patient us slate begin basket studi explor potenti activ solid
tumor gnaq mutat
take direct target inhibitor idya pipelin offer limit read
compani pipelin synthet lethal compound
focus base potenti near-term clinic valid target phase
develop compet compound agio expect idya move
lead compound ind enabl studi
furthermor encourag investor track idya progress wrn target lack obviou
bind domain offer signific challeng compound optim idya work
target optim year remain commit field multipl academ review
synthet lethal target identifi wrn among biolog import potenti
target address market potenti akin kra
take wrn could attract signific interest potenti partner idya optim
demonstr anti-tumor activ small patient cohort
valid moa pkc inhibit mum
long-term thesi potenti idya pipelin base potenti new synthet
lethal target lead program rel tradit small molecul target therapi
strong linkag pkc mutat gnaq
roughli mum patient mutat enzym gnaq accord
cancer genom atla tcga result constitut activ proteincoupl receptor
gpcr signal growth malign cell inhibit pkc downstream gnaq
may activ enzym prevent constitut activ gpcr signal
mani target agent resist may mitig combin regimen preclin
model suggest combin mek inhibitor may increas durabl respons
valid pkc oncogen
paper publish raamsdonk et al demonstr linkag mutat
tumor growth rate studi inject nonobes immune-incompet diabet mice mutant
melanocyt result exponenti tumor growth week compar wildtyp
melanocyt growth exhibit
exhibit induct tumor mutat variant mous model
raamsdonk et al mutat uveal melanoma new england journal medicin
furthermor raamsdonk et al demonstr mutant melanocyt directli contribut
tumorigenesi signal activity-depend manner oncogen gnaq paralog
upregul mitogen-activ protein kinas mapk signal lead uncontrol
cellular growth prolifer phosphoryl erk perk final protein mapk pathway
result activ downstream protein unsurprisngli perk level
mutant uveal cancer cell line elev uveal cell line level compar known
oncogen braf nra gene exhibit
raamsdonk et al mutat uveal melanoma new england journal medicin
find subsequ confirm tcga found high rate mutat
gene paralog gnaq uveal melanoma repres combin case
analyz cancer cell line regist rate exhibit
exhibit cancer distribut case mutat
tcga find consist epidemiolog place rate mutat
clinic case uveal melanoma describ yang et al articl entitl
treatment uveal melanoma publish februari issu
therapeut advanc medic oncolog
take strong rational develop target therapi
mutat uveal melanoma base high preval recent find suggest mutat
link mapk pathway signal
recent paper chen et al cancer cell identifi potenti link
mutat phosproyl protein kinas pkc mapk signal upregul
see exhibit author also found pkc-independ dag-medi recruit contribut
mapk signallingeexplain pkc inhibit suffic durabl supress mapk
exhibit pkc mediat mapk pathway activ gnaq mutant uveal melanoma
chen et al mediat mapk pathway activ gnaq mutant uveal melanoma cancer cell
short activ bound gtp result oncogen transform melanocyt
inhibit pkc downstream mapk signal partial
take inhibit pkc demonstr regul mapk signal whether effect size
larg enough result clinic benefit remain unclear
phase studi mum patient demonstr activ
describ origin develop novarti licens idya
prior licens novarti enrol mum patient mutat gene
patient receiv either singl agent combin inhibitor
protein bind transcript activ domain inhibit tumor
suppressor gene patient random receiv either daili dose mg
twice daili bid dose mg
primari endpoint incid dose limit toxic dlt incid sever
seriou advers event sae dose interrupt reduct dose intens secondari
endpoint overal respons rate orr per recist progression-fre surviv
per recist pk/pd read modul signal molecul downstream pkc
septemb idya report patient mg bid cohort
clinic benefit includ partial respons rate summar exhibit
exhibit respons data patient bid cohort
take view respons rate improv single-digit respons rate
often seen dtic chemotherapi believ larg number stabl diseas patient also
clinic import may translat superior
interim data updat august evalu patient continu therapi
year patient experienc partial respons diseas
progress month treatment overal respond surpass median os
approxim month seen exhibit way comparison idya conduct meta-
analysi phase ii clinic trial mum patient yield median
month median surviv month
exhibit durat exposur bid cohort
basket studi expand address market
tcga data suggest significantli higher rate mutat uveal
melanoma solid tumor cell line absolut incid uveal melanoma rel
low annual us gross number patient mutat
across solid tumor significantli larger total number uveal melanoma patient
take genet screen rate cancer patient continu increas support broad
clinic adopt find basket studi within next year least us driven
develop therapi tumor agnost indic
idya explor sever strategi expand address market shown exhibit
includ phase i/ii pkc fusion basket studi separ compani may
explor develop combin mek inhibitor boost durabl respons mum
base review tcga literatur monitor recruit three specif
subpopul basket studyuterin cancer colon cancer skin cutan melanoma
base rel high rate mutat tumor type shown exhibit
assumpt base pool expect preval rate loss
tcga gdc portal mum solid tumor uterin colon skin cutan tumor patient
histor cancer incid data collect north american associ central cancer
registri naccr estim cancer incid number american cancer societi
exhibit rate loss select tumor type
biomarkerpati populationsourc lossmetastat uveal melanoma tumor tcgauterin cutan melanoma skcm ideaya bioscienc
revenu forecast base use mum patient well uterin cancer colon cancer
skin cutan melanoma case mutat base signific unmet
need improv durabl respons boost median surviv mum rel
concentr distribut address patient popul academ medic center
includ econom use combin mek inhibitor may extend durabl
respons length time therapi
model segment revenu us row us market repres sale base
clear regulatori reimburs path target therapi wider use genet test
newli diagnos cancer patient expect launch us
europ
american diagnos uveal melanoma year accord american
cancer societi roughli half metastat patient anoth diagnos
uterin cancer posit address uterin cancer popul
furthermor patient diagnos colon cancer
patient present mutat patient diagnos skin
cutan melanoma patient present mutat
total arriv address market patient us use solid tumor
could repres upsid forecast row model exclud use outsid mum base
low level genet test result address market roughli mum patient
assum base price approxim per month per patient us row
minimum per patient treatment cours per month treatment price base
current parpi trki drug price minimum base expect
point refer exhibit review monthli cost parp inhibitor sever
therapi target gene fusion benchmark think price gener drug
serv market treatment alternait commad higher price view potenti
justifi premium price
exhibit averag price per month per patient target oncolog drug
model call captur address us mum market base limit
altern roughli row due like limit reimburs expect
penetr us solid tumor loss function modest
howev given larger patient popul patient account nearli total number
patient treat outsid us expect product sold partner
idya recogn tier royalti gross sale
expect idya recogn sale gross sale
month averag price per month treatmentp patient olaparib brca-mut advanc ovarian oncologyrubraca rucaparib brca-mut advanc ovarian advanc breast lilly-bay vitrakvi larotrectinib solid tumor ntrk fusionn/a dor pharmatarceva erlotinib nsclc egfr fusion-bas inhibitorsparp inhibitor companytrade/gener nameind idya outperform
synthet lethal futur direct idya pipelin
natur synthet lethal achiev mutat two gene regul singl essenti cellular
function result dysregul strand dna apoptosi cell contain one
mutat cell remain viabl amen dna repair mechan
therapeut synthet lethal base identfi patient high cencentr cell
malign tissu singl strand dna break associ specif genet mutat
disturbingeith remain singl dna strand regul dna repair path way
necessari fix demag strand theori therapeut intervent may promot apoptosi
tumor cell limit target impact healthi cell concept express exhibit
describ review articl titl synthet lethal framework develop wiser
cancer therapeut kaelin et al publish genom medicin
concept synthet lethal new improv access genet screen
necessari identifi appropri patient addit first-gener synthet lethal
compound target parp associ myelosuppress view
headwind clinic uptak
million except product growth rate melanoma patient patient number mum patient loss market annual number patient treat month therapi per per month increas price per per patient per treatment cours sale mum patient tumor patient uterin corpu endometri carcinoma ucec uterin carcinoma patient number ucec/uc patient adenocarcinoma patient number coad patient cutan melanoma skcm patient number skcm patient number solid tumor market annual number patient treat month therapi per per month increas price per per patient per treatment cours sale solid tumor patient sale uveal melanoma patient total patient number ex-u mum patient loss market annual number patient treat month therapi per per month increas price per per patient per treatment cours sale ex-u patient rate ex us revenu idya revenu ideaya bioscienc
exhibit conceptu overview synthet lethal
kaelin synthet lethal framework develop wiser cancer therapeut genom
earli hartwel et al propos idea use synthet lethal altern
chemotherapi paper entitl integr genet approach discoveri anti-cancer
drug author note challeng therapeut synthet lethal difficulti understand
complex mammalian cell signal circuitri limit method assess molecular
alter tumor rel ineffect method condit inactiv gene
take progress assess molecular alter revolution drug
develop condit inactiv gene biochemistri bioengin address
two three challeng synthet lethal drug develop view understand cell
signal pathway continu headwind class
recent studi creat hiearchi synthet lethal target
advent crispr technolog sever academ group sought replic
condit synthet lethal intervent single-strand target dna break evalu
biolog activ potenti therapeut target differ cancer cell line
take recent paper sanger institut broad creat roadmap priorit
potenti target synthet lethal like acceler invest sector
sanger institut publish method use crispr screen priorit cancer
therapeut target describ april issu natur lab screen human cancer
cell line cancer type target identifi cell fit effect integr
genom biomark target tractabl drug develop determin drug develop
priorit describ exhibit
pan-canc core fit gene identifi use adapt daisi model adam elimin
analysi unlik core fit gene like involv essenti process cell
context-specif gene requir cell fit specif molecular histolog context
make attract drug target due reduc likelihood toxic healthi tissu
context-specif fit gene sanger institut use comput framework
nomin promis target import assign experiment evid
base evid genet biomark associ target depend frequenc
behan et al priorit cancer therapeut target use screen natur
total uniqu prioriti target identifi pan-canc cancer-typ specif
target tractabl assess rank suitabl pharmaceut intervent
perform target score scale stratifi group approv drug
clinical/preclin develop support evid weak support evid
exhibit summar notabl target rank divid tractabl cancer indic
behan et al priorit cancer therapeut target use screen natur
wrn emerg import target
would note wrn emerg sanger institut work import potenti target ovarian
colon cancer prioriti score compar kra find corrobor chan et al
broad institut concurr april public wrn inactiv msi-high cell
studi publish research letter describ potenti mechan wrn
inactiv induc double-strand break respons promot cell death cell cycl arrest
take develop drug candid wrn helicas like challeng due
absenc obviou bind domain multipl studi support focus wrn potent
assess competit landscap synthet lethal challeng due rel immatur
pipelin compani group limit disclosur privat held compani
exhibit provid overview sever key competitor base disclos target
interest list exhausit import trend emerg includ high level
competit drug polq rel broad pipelin compani
expect signific level segment among competitor base use synthet lethal
target direct cell-kil strategi synthet lethal strategi broaden use immuno-
exhibit overview synthet lethal competit landscap
compani report oppenheim co inc estim
tango privat held biotechnolog compani back third ventur develop
synthet lethal platform combin crispr biomark includ tumor suppressor loss
immun evas unmark oncogen discov new druggabl target tango sign
strateg partnership perform target discoveri valid
target separ tango present data meet valid synthet
lethal target mutant ovarian cancer cell
repar privat held biotechnolog compani focus synthet lethal interact exploit
ddr defect genom instabl like tango rapar use genom edit
identifi druggabl target repar part cancer depend map depmap consortium
launch broad institut bring togeth academia industri identifi cancer
vulner compani identifi import synthet lethal target interest
sl ovarianc cancerxatrdna replic stress target undisclos biomark xxxxxxx consist large-cap pharmaceut compani idya outperform
ksq use crispr-en function genom includ proprietari tool
refer crisprom optim broad drug discoveri pipelin encompass adopt cell
therapi immuno-oncolog target oncolog immuno-regul
artio ddr-focus precis oncolog compani lead target candid in-licens
cancer rusearch uk cruk target includ second undisclos ddr target dna
nucleas artio privat held fund pfizer ventur novarti ventur fund
impact china-bas clinical-stag compani focus valid ddr target includ parp
sever well-valid consider optim small molecul inhibitor includ
potenc select molecular weight ligand/hydrophil effici overal drug-lik
lipinksi rule academ partnership idya develop librari synthet
lethal interact dual crispr screen two gene knock outspecif
one encod tumor suppressor anoth encod put synthet lethal target
method queri synthet lethal interact valid use date
idya cross known tumor suppressor gene ddr pathway-rel drug target
identifi idya use bioinformat public well proprietari databas better
character interact summar exhibit
databas use support drug optim includ novarti project drive cancer genom
atla tcga broad institut project achil mskcc impact aacr project geni
genom project nih genotyp tissu express portal
parallel compound optim idya work diagnost compani identifi screen
technolog appropri drug target exhibit highlight current diagnost
partner therapeut develop program
mtap commonli mutat loss function metabol driver mutat cancer patient
intract due part potenti role enzym healthi malign tissu
term mechan action mtap delet confer enhanc depend
ariginin methyltransferas downregul tumor suppressor gene cancer cell
mtap delet occur cancer preval glioblastoma gbm
melanoma carcinoma exhibit
take exploit vulner result mtap delet widespread use potenti
efficaci cancer especi import gbm surviv rate
lack treatment option
due mtap delet cancer cell accumul high level mta inhibit
methyltransferas activ exhibit sinc mtap still ubiquit express healthi cell
deplet expect result unaccept advers event
exhibit overview pathway
marjon et al mtap delet cancer creat vulner target axi cell report
current idya multipl inhibitor compound develop combin
high-throughput screen scaffold morph exhibit exampl potent high-resolut
x-ray co-cryst structur inhibitor bound protein
take defin crystal structur help idya optim potent inhibitor target
main focu compound safeti profil establish clinic relev inhibit
idya demonstr inhibitor may select
compound agio exhibit high ratio inhibit wildtyp cell
vs cell mtap delet
exhibit idya may potent inhibitor agio
wrn still earli potenti hot cancer research
werner syndrom protein wrn human recq helicas associ maintain genom
stabil synthet lethal target cancer cell high microsatellit instabl high-msi
msi-high accord kategaya et al april articl entitl werner syndrom helicas
requir surviv cancer cell microsatellit instabl high-msi cancer mark
specif mismatch repair gene includ endometri ucec colorect coad
tcga found mutat preval ucec case studi cnv
melanoma case mutat biomark high-msi howev indic
may cancer elev rate high-msi statu
exhibit cancer distribut case mutat
high-msi caus mutat mismatch repair mmr acceler mutat
destabil genom vulner wrn depletion-medi apoptosi
exhibit synthet lethal interact high-msi wrn
kategaya et al werner syndrom helicas requir surviv cancer cell microsatellit instabl iscienc
lieb et al demonstr select depend wrn msi-high cell transient knock
wrn mss msi-high colorect cancer line see exhibit
exhibit loss wrn function msi-high caus sever chromosom defect
lieb et al werner syndrom helicas select vulner microsatellit instability-high tumor cell elif
follow wrn deplet high-msi cell lieb et al also observ rapid loss cell viabil due
genom instabl character chromosom break chromatin bridg micronuclei
take wrn deplet msi-high cell highli potent genom instability-medi apoptosi
lastli idya made progress improv wrn inhibitor potenc seen exhibit
improv potenc first gener end gener compound
exhibit improv potenc wrn inhibitor
polq popular target ddr
polq encod pol- enzym synthes molecul deoxyribonucleotid
specif describ mateos-gomez et al mammalian polymeras theta promot
alternative-nhej suppress recombin pol- stimul microhomology-medi end-
join mmej altern end-join nhej machineri trigger respons double-strand
break dna word pol- import role spell-check replic code
maintain genom stabil essenti role polq genom stabil make synthet
lethal target homologous-recombination-defici hr-defici cancer identifi
varieti biomark includ hdr homolog direct repair mutat
tcga network paper integr genom analys ovarian carcinoma estim
epitheli ovarian cancer case sequenc hr-defici exhibit
exhibit cancer distribut case hdr mutat
polq consist upregul hr-defici cancer importantli ceccalidi et al
homolog recombination-defici tumor hyper-depend polq-medi repair
show knock polq human ovarian cancer cell line shrna select
confer sensit doxorubicin parp inhibit parpi exhibit contrast wildtyp
ovarian cancer cell infect shrna respond well doxorubicin parp inhibit
exhibit polq mutat confer potenti sensit chemotherapi
ceccalidi et al homolog recombination-defici tumor hyper-depend polq-medi repair natur
idya even multipl mechan inhibit describ exhibit
exhibit potenc idya pol-theta compound
parg inhibitor long clinic
parp-inhibitor demonstr efficaci frontlin mainten monotherapi brca-mut
epitheli ovarian cancer eoc best-known class synthet lethality-bas small
molecul inhibitor date fda-approv parp inhibitor olaparib rucaparib niraparib
talazoparib brca-mut ovarian cancer repres ovarian cancer howev
parp parg synthet lethal high-ddr ovarian cancer target function
differ mechan specif parg inhibit synthet lethal high frequenc
dna damag repair high-ddr see exhibit
exhibit parg inhibit high dna damag repair high-ddr ovarian cancer
pillay et al dna replic vulner render ovarian cancer cell sensit poli adp-ribos glycohydrolas inhibitor
take parg offer altern pathway defici ovarian cancer
queri synthet lethal target use high-ddr parg pillay et al found sever protein
involv dna replic replic stress timeless
author note decreas prolifer presenc stain yellow cell viabil
due parg inhibit high-ddr inhibit patient-deriv ovarian cancer cell line
exhibit pargi synergist impact ovarian cancer cell
pillay et al dna replic vulner render ovarian cancer cell sensit poli adp-ribos glycohydrolas inhibitor
noteworthi parg inhibit alon effect control dmso background
potenti indic low toxic normal cell cancer cell without high-ddr
date idya identifi parg inhibitor less nm potenc drug-lik
attribut includ foci cell potenc solubl ph herg
expect idya continu reli partnership sourc know-how drug target
valid potenti strategi expand develop pipelin target therapi
among compani five current partnership three academ group one access
diagnost test expertis necessari select patient clinic trial final agreement
novarti cover commerci right
take mid-to-high single-digit royalti novarti may creat hurdl sublicens right
outsid us prior complet clinic develop
novarti institut biomed research nibr commerci right
septemb idya licens global commerci right re-nam
novarti receiv up-front payment cash share idya seri
redeem convert stock valu idya also respons addit
develop sale mileston well mid-to-high single-digit royalti net sale
drug discoveri cancer research uk cruk univers manchest licens
world-wide develop commerci right poli adp-ribos glycohydrolas parg
inhibitor idya april idya exercis commerci option follow complet
toxicolog studi cruk receiv up-front fee one-tim licens fee
furthermor subject complet certain regulatori clinic mileston idya
respons mileston payment per indic sale mileston total addit
per indic cruk also entitl low single-digit tier royalti low mid-teen
percentag sublicens revenu
univers california san diego ucsd research collabor
compani work trey idek professor medicin bioengin ucsd
evalu function genom comput biolog better understand gene-gen pathway
interact specif lab conduct dual crispr screen key node dna damag
repair pathway tumor suppressor gene identifi addit
univers california san francisco research collabor
lab sourav bandyopadhyay ucsf idya collabor identifi valid novel
like target therapi drug idya pipelin program requir diagnost test
identifi patient genet variant may respons therapi compani work
foundat medicin divis roch adapt foundationon assay screen
undisclos marker assum
expect idya reli third parti contract manufactur organ cmo manufactur
api fill-finish compound sta pharmaceut hong kong ltd
divis wuxi apptec respons manufactur drug product divis
icon plc respons product distribut conduct clinic trial
take given compani pipelin program small molecul expect
multipl effici produc api view manufactur process develop
core skill necessari commerci idya pipelin
march idya control patent applic distinct patent famili cover
composit method use advanc pipelin program structur
patent portfolio follow issu patent pend patent applic foreign-
issu patent pend foreign applic approxim jurisdict across north
america europ asia patent expir
portion patent portfolio compris issu patent foreign-issu patent
pend applic pend applic jurisdict
take patent attorney patent applic entitl
inhibitor treat uveal melanoma describ composit appear offer broadest
potenti patent protect patent term
furthermor idya control pend patent applic direct method treatment
certain solid tumor mutat certain solid tumor pkc fusion certain
egfr mutant tumor nsclc patent grant may offer protect
given limit prior art synthet lethal would expect compani in-hous
synthet lethal discoveri program enjoy composit matter protect commerci
expect compani incur addit futur oper loss achiev
profit may gener addit tax asset off-set futur tax oblig base
financi project expect tax asset off-set first three-plu year profit
subsequ period expect compani recogn effect tax rate
term us tax asset idya feder net oper loss carryforward
state net oper loss decemb believ portion tax asset may
subject impair expect impair materi outlook
idya develop stage compani view measur financi metric
sale growth ep potenti launch encourag investor
focu clinic develop regulatori mileston pipelin program
primari avenu creation sharehold valu
manag provid financi guidanc given recent complet ipo may
view histor data oper expens may predict futur expens trend
forecast cash burn current cash balanc fund oper
middl
sale includ revenu near-term outlook expect drug
begin record revenu contribut
cog includ tier mid-to-high singl digit royalti payabl novarti expect
enjoy gross margin commerci scale product
 expect expens increas substanti due
increment expens public compani estim driven full year
public compani expens
sale market expect idya incur meaning sale market expens
model call compani hire sale peopl support us launch
peak sale forc around rep
 forecast call spend acceler compani complet
phase i/ii studi mum basket studi solid tumor gnaq variant
forecast call total spend versu expect
 spend
ep expect idya record pro forma ep respect
expect compani achiev profit
compani complet ipo may common stock ideaya bioscienc trade
ticker idya june execut offic director
control idya common stock ventur investor includ ventur canaan
manag still control biotechnolog valu fund partner control
outstand stock percept advisor own compani addit celgen own
share net believ concentr institut ownership may limit trade
liquid near term see exhibit
compani total million outstand employe stock option warrant fulli
dilut basi estim idya million share outstand
compani debt
march san franciscobas idya full-tim employe part-tim employe
includ busi develop financ legal manag net
view manag experi overse oncolog portfolio big pharma biotech
compani appropri idya near term oper requir next month
expect compani add personnel clinic oper begin ad expertis market
develop commerci prepar potenti approv
presid chief execut offic yujiro hata co-found idya serv chief
execut sinc prior idya flexu bioscienc compani
acquir bristol-my squibb addit serv head corpor
develop strategi acquisit
mr hata receiv ba chemistri colorado colleg mba wharton school
univers pennsylvania member board expans
chief scientif offic michael dillion began work idya current serv
senior vice presid chief scientif offic previous held sever leadership role
novarti institut biomed research includ posit execut director oncolog
chemistri led develop target therapi work
mutant b-raf kinas inhibitor encorafenib addit serv director medicin chemistri
syntex part roch dr dillon receiv bs chemistri univers
leicest phd chemistri univers bristol complet post-doctor fellowship
chemistri oregon state univers
chief financi offic paul stone join idya gener counsel may name
cfo mr stone affili serval ventures-back compani includ
cidara ilypsa entrada
mr stone practic intellectu properti law sennig power llp receiv bs chemic
engin univers wisconsin jd univers wisconsin law school
chief medic offic juli hambleton chief medic offic idya sinc prior
work compani head develop bristol myer
role includ prime vice-president clinic develop
group medic director among role genentech
holdershar total ventur partner advisor life scienc manag compani asset manag ideaya bioscienc
ms hambleton receiv bs nurs duke univers md case western
univers school medicin complet medic train special hematology-
oncolog ucsf also faculti member
risk idya includ clinic trial failur phase i/ii studi studi
compani oral pkc inhibitor current cash balanc suffici fund oper beyond
middl pkc repres novel target target drug develop fulli
valid prior clinic trial uncertain clinic relev much compani
portfolio may commerci partnership
primari product underpin invest thesi idya research spend
compani candid furthest along clinic repres import opportun
valid pkc inhibit import target treat solid tumor success phase i/ii
mum studi may provid meaning catalyst convers failur may rais doubt prospect
separ phase i/ii basket studi patient gnaq variant tumor type
idya enough cash base forecast fund oper middl howev
cash balanc suffici fund registr studi compani unabl access
suffici capit attract term idya may need slow pace futur clinic develop
potenti pkc inhibit regul gnaq mediat gtpase express
valid preclin model clinic studi clinic import gnaq
regul reduc tumor burden extend either surviv
idya product portfolio includ may commerci partnership
may spread potenti risk drug failur idya upsid may also reduc
assur partner alloc adequ support complet clinic trial time manner
maxim commerci uptak outsid us
compani report oppenheim co inc estim
research profit profit loss per share continu incom loss loss per share averag common ideaya bioscienc
compani report oppenheim co inc estim
short term current properti account accru current equiti paid-in accumul comprehens accumul deficit sharehold idya outperform
stock price compani mention report
